Company Overview

Update
Founders:
Marwan Fawaz
Headquarters:
Cambridge, MA
IPO:
Went Public on Jan 1, 2000
Stock:
NASDAQ:SRPT
Categories:
Biotechnology

Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to improve and save

Description

Update

Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Sarepta’s unique technology has yielded a diverse pipeline of RNA-based therapeutics that include their lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world’s most lethal infectious diseases.

Current Team (3)

Update

Offices/Locations (1)

Update
  • Office

    245 First Street

    Suite 1800

    Cambridge, MA 02142

    USA

Images (1)

Update
  • 61039d405272762c10f3db7064de3dda